Please login to the form below
Esmya
This page shows the latest Esmya news and features for those working in and with pharma, biotech and healthcare.
FDA rejects Allergan’s uterine fibroid drug over safety concerns
Allergan’s selective progesterone receptor modulator is already approved in Europe, where it is sold as Esmya (ulipristal acetate) and marketed by Hungarian pharmaceutical company Gedeon Richter. ... The findings were backed up by the EMA’s
Latest news
-
MHRA suspends new prescriptions of fibroid drug Esmya
is a causal relationship between Esmya and liver injury, and indeed no cases of liver injury were observed in controlled clinical trials”. ... Analysts have suggested that Esmya could be an $800m product for Allergan if it secures US approval.
-
Allergan on course to file uterine fibroid drug next year
The company is developing ulipristal acetate for fibroids in collaboration with Gedeon Richter, which has sold the drug in Europe as Esmya since 2012, although only as a pre-treatment for
-
PregLem and Merck to address adhesion need
In addition, PregLem has received positive phase III data on its lead drug candidate, Esmya (ulipristal acetate), for the treatment of uterine fibroids (myoma).
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Humancomms for humancare?
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Genmab hires first chief operating officer
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
